Pulmonary complications remain a primary cause of morbidity and mortality in Parkinson’s disease (PD). Obstructive and restrictive airway deficits are related to disordered motor control of the respiratory musculature. Although this may sometimes lead to overt symptoms, such as stridor and respiratory failure, it more commonly results in silent aspiration and atelectasis, predisposing patients to pneumonia. Anti-Parkinson medications may produce pulmonary side effects (e.g., pleuropulmonary fibrosis associated with ergot-based dopamine agonists). Finally, motor fluctuations in patients with advanced PD may affect the respiratory system. Recognizing these pulmonary complications will assist the clinician in appropriately managing the disease and potentially reducing the impact of the abnormal respiratory system on the overall health of the patient with PD.